BCAX insider sale by Ryan Cohlhepp

Ryan Cohlhepp reported sales of common stock of BCAX on Form 144.

Accepted by SEC EDGAR 02/25/2026 - 04:03 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Ryan Cohlhepp reported sales of common stock of BCAX on Form 144.

The filing lists three reported sales: 12/15/2025 of 12,500 shares for $233,547.50; 01/15/2026 of 149 shares for $2,684.98; and 01/22/2026 of 3,828 shares for $69,295.99.

The excerpt also lists securities to be sold via exercise of stock options: 523 shares on 05/12/2024 and 3,108 shares on 02/25/2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transactions did Ryan Cohlhepp report for BCAX?

He reported three sales of common stock: 12,500 shares on 12/15/2025, 149 shares on 01/15/2026, and 3,828 shares on 01/22/2026. The filing lists cash proceeds for each sale alongside the dates.

What proceeds were disclosed for the BCAX sales by Cohlhepp?

The filing discloses proceeds of $233,547.50 (12/15/2025), $2,684.98 (01/15/2026), and $69,295.99 (01/22/2026). Each amount is shown next to the corresponding sale date and share count.

Does the Form 144 show any planned exercises or future sales for BCAX?

Yes, it lists securities to be sold from stock option exercises: 523 shares with an exercise date of 05/12/2024 and 3,108 shares with an exercise date of 02/25/2026. No further timing details are provided in the excerpt.

Which security type and exchange are shown in the excerpt for BCAX?

The excerpt identifies the security as Common stock and lists NASDAQ as the exchange. Specific share counts and exercise/sale dates associated with those common shares are included in the filing excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002034665
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Bicara Therapeutics Inc.
SEC File Number	001-42271
Address of Issuer	116 HUNTINGTON AVENUE SUITE 703 BOSTON MASSACHUSETTS 02116
Phone	617-468-4219
Name of Person for Whose Account the Securities are To Be Sold	Cohlhepp Ryan
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc Eleven Madison Avenue 4th Floor New York NY 10010	3631	65501.42	54781950	02/25/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/12/2024	Exercise of Stock Option	Issuer			523	05/12/2024	Cash
Common	02/25/2026	Exercise of Stock Option	Issuer			3108	02/25/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Ryan Cohlhepp 116 HUNTINGTON AVENUE SUITE 703 Boston MA 02116	Common	12/15/2025	12500	233547.50
Ryan Cohlhepp 116 HUNTINGTON AVENUE SUITE 703 Boston MA 02116	Common	01/15/2026	149	2684.98
Ryan Cohlhepp 116 HUNTINGTON AVENUE, SUITE 703 Boston MA 02116	Common	01/22/2026	3828	69295.99

144: Remarks and Signature

Remarks
Date of Notice	02/25/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/12/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc., as attorney-in-fact for Ryan Cohlhepp
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)